Abstract
Background Access to diagnostics was a significant challenge during the early stages of the COVID-19 pandemic, as laboratory reagents, supplies, and consumables were in short supply and high demand. Central laboratories, equipped with advanced real-time PCR equipment and highly skilled staff, worked long hours to produce test results for travellers, hospital patients, and the general public. We developed a SARS-CoV-2 molecular diagnostic assay suitable for point-of-care testing to address this diagnostic challenge.
Methods Recombinase amplification coupled with fluorescent detection was chosen as the technology, as it was freely available. Using a mobile fluorescent detection device ensures foolproof results interpretation, point-of-care testing and minimal footprint in facilities. Designed as a one-step reverse transcriptase real-time isothermal assay utilising the FAM and ROX channels. Specimens were tested using commercially available real-time PCR assays to evaluate the performance characteristics of the assay.
Results The SARS-CoV-2 Isothermal Molecular Assay (SIMA) detects the SARS-CoV-2 ORF1ab gene and a human gene to differentiate poor specimen collection. SIMA runs at 40°C for 36 minutes, with the first six minutes dedicated to reverse transcription. It has a detection limit of 555 RNA copies/mL. Highly positive specimens are detected within three minutes, but the 30-minute run time allows for detecting low-positive Specimens. Sensitivity was 95%, with 100% specificity, while precision ranged from 4% to 6%
Conclusions We report the performance characteristics of SIMA, the first molecular diagnostics developed in Nigeria for SARS-CoV-2 point-of-care diagnosis. Its performance and utility give hope for rapid diagnosis and treatment in resource-constrained settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the grant support from the Fate Philanthropy Coalition against COVID-19 (FPCC) Support Fund, which enabled the design and development of SIMA amid the COVID-19 pandemic lockdown
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee/IRB of the Nigerian Institute of Medical Research, Nigeria, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos